MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-05-2024
Catalent Operating Cash Flow 2011-2026 | CTLT
Annual Operating Cash Flow Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 268 M | 254 M | 439 M | 433 M | 440 M | 248 M | 374 M | 300 M | 155 M | 172 M | 178 M | 138 M | 87.9 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 440 M | 87.9 M | 268 M |
Quarterly Operating Cash Flow Catalent
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 61 M | - | - | - | -70 M | - | - | - | -92 M | 122 M | - | - | 163 M | 232 M | - | - | 150 M | 224 M | 150 M | - | 25.2 M | 146 M | 25.2 M | - | 41.2 M | 84.5 M | 41.2 M | - | 83.7 M | 176 M | 83.7 M | - | 48.3 M | 96 M | 48.3 M | - | 44.9 M | 71.5 M | 44.9 M | - | -39.8 M | 400 K | -39.8 M | - | 25.2 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 232 M | -92 M | 69.5 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.19 | - | $ 128 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | USA |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 13.9 | - | $ 712 M | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | $ 21.5 | - | $ 2.05 B |  France |
 |
Evolus
EOLS
|
-18 M | $ 5.66 | - | $ 351 M | USA |
 |
Harrow Health
HROW
|
3.84 M | $ 51.0 | -4.67 % | $ 1.66 B | USA |
 |
China Pharma Holdings
CPHI
|
-466 K | $ 1.35 | 5.88 % | $ 23.6 M |  China |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.65 | - | $ 3.37 M | Canada |
 |
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.68 | - | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 7.9 | 3.47 % | $ 2.88 B | Canada |
 |
Pacira BioSciences
PCRX
|
189 M | $ 26.0 | - | $ 1.2 B | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 5.19 | - | $ 73 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 3.74 | -1.58 % | $ 4.64 M | USA |
 |
Organogenesis Holdings
ORGO
|
14.2 M | $ 4.3 | - | $ 566 M | USA |
 |
Aurora Cannabis
ACB
|
-211 M | $ 4.24 | - | $ 86.3 M | Canada |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Veru
VERU
|
-21.7 M | $ 2.37 | 1.72 % | $ 320 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Perrigo Company plc
PRGO
|
363 M | $ 14.59 | -1.19 % | $ 2 B | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Rockwell Medical
RMTI
|
-9.41 M | $ 0.95 | 2.78 % | $ 22.2 M | USA |
 |
cbdMD
YCBD
|
-353 K | $ 1.1 | - | $ 4.74 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.32 | 5.88 % | $ 130 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
49.6 M | $ 9.43 | -1.05 % | $ 670 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-100 M | $ 5.61 | - | $ 229 M | USA |
 |
SCYNEXIS
SCYX
|
60.2 M | $ 0.64 | - | $ 30.6 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
7.91 M | $ 8.99 | - | $ 5.56 B | Canada |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.04 | - | $ 21.3 M | USA |
 |
Viatris
VTRS
|
3 B | $ 12.46 | - | $ 15.1 B | USA |
 |
Zomedica Corp.
ZOM
|
-16 M | - | -0.21 % | $ 98 M | USA |